Peter Lindgren

Publications
Grants
CV
Public outreach and news

Articles

Article: BLOOD PRESSURE. 2025;34(1):2487583
Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden
Kahan T; Johansen ML; Ryschon AM; Cao KN; Kolovetsios MD; Lindgren P; Pietzsch JB
Journal article: ESMO OPEN. 2025;10:105009
437P Benchmarking breast cancer survival: A case-mix model for fair hospital comparisons of 5 and 10-year breast cancer-specific mortality
Thurell J; Petrov I; Lindgren P; Bergh J; Fredriksson I; Kiani N; Hedayati E
Article: PHARMACOECONOMICS - OPEN. 2025;9(2):161-178
Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations
Thokala P; Duarte H; Wright S; Husereau D; Durand-Zaleski I; Lindgren P; Postema R; Machnicki G; Garrison L
Article: JOURNAL OF MEDICAL ECONOMICS. 2024;27(1):1146-1156
Societal costs and quality of life associated with arginase 1 deficiency in a European setting - a multinational, cross-sectional survey
Olofsson S; Lofvendahl S; Widen J; Rudebeck M; Lindgren P; Stepien KM; Arnoux J-B; Pico MLC; Teles EL; Jacobson L
Journal article: VALUE IN HEALTH. 2024;27(12):s276
HPR6 Early Access Programs in Northwest European Countries
Birch C; Brådvik G; Larsen E; Lindgren P; Ehlers L
Article: JIMD REPORTS. 2024;65(6):450-460
Disease burden among patients with Arginase 1 deficiency and their caregivers: A multinational, cross-sectional survey
Olofsson S; Lofvendahl S; Widen J; Jacobson L; Lindgren P; Stepien KM; Arnoux J-B; Pico MLC; Teles EL; Rudebeck M
Journal article: VALUE IN HEALTH. 2023;26(12):s196-s197
EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence
Kahan T; Johansen ML; Ryschon AM; Cao K; Kolovetsios M; Lindgren P; Pietzsch J
Article: VALUE IN HEALTH REGIONAL ISSUES. 2023;37:81-87
The Disease Burden and Economic Burden of Cancer in 9 Countries in the Middle East and Africa
Hofmarcher T; Garcia AM; Wilking N; Lindgren P
Article: FRONTIERS IN NEUROLOGY. 2023;14:1175922
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Tate A; Suarez-Calvet M; Ekelund M; Eriksson S; Eriksdotter MM; Van der Flier W; Georges J; Kivipelto MG; Kramberger M; Lindgren P; Lopez JDG; Lotjonen J; Persson S; Pla S; Solomon A; Thurfjell L; Wimo A; Winblad B; Jonsson L
Article: NATURE REVIEWS UROLOGY. 2023;20(8):494-501
Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium.
Omar MI; MacLennan S; Ribal MJ; Roobol MJ; Dimitropoulos K; van den Broeck T; MacLennan SJ; Axelsson SE; Gandaglia G; Willemse P-P; Mastris K; Ransohoff JB; Devecseri Z; Abbott T; De Meulder B; Bjartell A; Asiimwe A; N'Dow J; PIONEER Consortium
Journal article: TOBACCO PREVENTION AND CESSATION. 2023;9(Supplement)
Motivation 2 Quit (M2Q): Tobacco Cessation on Prescription – an effective treatment?
Tomson T; Leppänen A; Lindgren P; Sundberg CJ; Petzold M
Article: VALUE IN HEALTH. 2023;26(4):3-10
Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
de Pouvourville G; Cunningham D; Fricke F-U; Lindgren P; Mantovani L; Murphy LA; Sola-Morales O; Mestre-Ferrandiz J; Akehurst R
Article: BLOOD PRESSURE MONITORING. 2023;28(2):86-95
Real-world long-term effects on blood pressure and other cardiovascular risk factors for patients in digital therapeutics
Willis M; Darwiche G; Carlsson M; Nilsson A; Wohlin J; Lindgren P
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2023;24(3):483
Reply to: making the rules make sense: valuation of constrained resources
Lindgren P
Article: VALUE IN HEALTH. 2023;26(3):328-335
The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom.
Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: FRONTIERS IN MEDICINE. 2023;10:1119506
A global analysis of the value of precision medicine in oncology - The case of non-small cell lung cancer
Hofmarcher T; Malmberg C; Lindgren P
Journal article: VALUE IN HEALTH. 2022;25(12):s156
EE510 A Global Analysis of the Value of Precision Medicine in Oncology – The Case of Non-Small Cell Lung Cancer
Hofmarcher T; Malmberg C; Lindgren P
Journal article: VALUE IN HEALTH. 2022;25(12):s91-s92
EE198 Integrating Health Economic Analysis into External Quality Assessment of Laboratory Tests: Evaluating Costs and Consequences of Bias in Lipid Tests in the Prevention of Cardiovascular Disease in Swedish Diabetes Patients
Keel G; Karlsson M; Tähti S; Galkus L; Örneholm F; Lindgren P
Article: PLOS ONE. 2022;17(12):e0278369
Motivation 2 Quit (M2Q): A cluster randomized controlled trial evaluating the effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare
Leppanen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: JOURNAL OF CANCER POLICY. 2022;34:100362
Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe
Hofmarcher T; Lindgren P; Wilking N
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(8):1259-1261
Breaking the rules: decision-making under absolute resource constraints
Lindgren P
Article: PHARMACOECONOMICS. 2022;40(11):1095-1105
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates
Di Tanna GL; Angell B; Urbich M; Lindgren P; Gaziano TA; Globe G; Stollenwerk B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2022;23(6):1059-1070
Value appropriation in hepatitis C
Lindgren P; Lofvendahl S; Bradvik G; Weiland O; Jonsson B
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2022;8(1):31-38
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
Landmesser U; Lindgren P; Hagstrom E; Hout BV; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Article: NEUROLOGY AND THERAPY. 2021;10(2):919-940
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2021;22(6):851-854
Something borrowed, something new: measuring hospital performance in the context of value based health care
Lindgren P; Althin R
Article: JOURNAL OF VIRAL HEPATITIS. 2021;28(1):142-146
Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals
Lindgren P; Lofvendahl S; Bradvik G; Weiland O
Article: DIABETOLOGIA. 2020;63(12):2582-2594
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Steen Carlsson K; Jendle J
Journal article: VALUE IN HEALTH. 2020;23:s493
PCV38 The IMPACT on Clinical an Economic VALUE of Patient Prioritization According to Risk: Evolocumab in Patients with Myocardial Infarction in Sweden
Hagström E; Lindgren P; Villa G; Martinez L; Arellano J; Svensson ME; Fonarow GC
Article: BRITISH JOURNAL OF SPORTS MEDICINE. 2020;54(21):1294-1299
A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group
Journath G; Hammar N; Vikstrom M; Linnersjo A; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Article: BMC EMERGENCY MEDICINE. 2020;20(1):85
Healthcare pathways and resource use: mapping consequences of ambulance assessment for direct care with alternative healthcare providers
Varg S; Vicente V; Castren M; Lindgren P; Rehnberg C
Article: DIABETES OBESITY & METABOLISM. 2020;22(9):1586-1597
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden
Persson S; Johansen P; Andersson E; Lindgren P; Thielke D; Thorsted BL; Jendle J; Carlsson KS
Journal article: NATURE REVIEWS UROLOGY. 2020;17(8):482
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; PIONEER Consortium
Article: NATURE REVIEWS UROLOGY. 2020;17(6):351-362
Introducing PIONEER: a project to harness big data in prostate cancer research
Omar MI; Roobol MJ; Ribal MJ; Abbott T; Agapow P-M; Araujo S; Asiimwe A; Auffray C; Balaur I; Beyer K; Bernini C; Bjartell A; Briganti A; Butler-Ransohoff J-E; Campi R; Cavelaars M; De Meulder B; Devecseri Z; Voss MD; Dimitropoulos K; Evans-Axelsson S; Franks B; Fullwood L; Horgan D; Smith EJ; Kiran A; Kivinummi K; Lambrecht M; Lancet D; Lindgren P; MacLennan S; MacLennan S; Nogueira MM; Moen F; Moinat M; Papineni K; Reich C; Reiche K; Rogiers S; Sartini C; van Bochove K; van Diggelen F; Van Hemelrijck M; Van Poppel H; Zong J; N'Dow J; Andersson E; Arala H; Auvinen A; Bangma C; Burke D; Cardone A; Casariego J; Cuperus G; Dabestani S; Esperto F; Fossati N; Fridhammar A; Gandaglia G; Tandefelt DG; Horn F; Huber J; Hugosson J; Huisman H; Josefsson A; Kilkku O; Kreuz M; Lardas M; Lawson J; Lefresne F; Lejeune S; Longden-Chapman E; McVie G; Moris L; Mottet N; Murtola T; Nicholls C; Pang KH; Pascoe K; Picozzi M; Plass K; Pohjanjousi P; Reaney M; Remmers S; Robinson P; Schalken J; Schravendeel M; Seisen T; Servan A; Shiranov K; Snijder R; Steinbeisser C; Taibi N; Talala K; Tilki D; Van den Broeck T; Vassilev Z; Voima O; Vradi E; Waldeck R; Weistra W; Willemse P-P; Wirth M; Wolfinger R; Kermani NZ
Article: BMJ OPEN. 2020;10(6):e032573
Time-driven activity-based costing for patients with multiple chronic conditions: a mixed-method study to cost care in a multidisciplinary and integrated care delivery centre at a university-affiliated tertiary teaching hospital in Stockholm, Sweden
Keel G; Muhammad R; Savage C; Spaak J; Gonzalez I; Lindgren P; Guttmann C; Mazzocato P
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):e19051
A comparative study on costs of cancer and access to medicines in Europe.
Wilking NE; Brådvik G; Lindgren P; Svedman C; Jönsson B; Hofmarcher T
Journal article: VALUE IN HEALTH. 2020;23:s172
PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C
Löfvendahl S; Brådvik G; Weiland O; Lindgren P
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49
The cost of cancer in Europe 2018
Hofmarcher T; Lindgren P; Wilking N; Jonsson B
Article: JOURNAL OF MULTIDISCIPLINARY HEALTHCARE. 2019;12:1075-1083
Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic
Rafiq M; Keel G; Mazzocato P; Spaak J; Guttmann C; Lindgren P; Savage C
Journal article: VALUE IN HEALTH. 2019;22:s548
PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Sibartie M; Fonarow GC
Journal article: VALUE IN HEALTH. 2019;22:s685
PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE
Berdud M; Bernhardsson NW; Talaya MBZ; Lindgren P; Towse A
Journal article: EUROPEAN HEART JOURNAL. 2019;40(Supplement_1):ehz748.0183
P1225Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
Lindgren P; Hagstrom E; Van Hout B; Villa G; Urbich M; Sandelin R; Svensson ME; Fonarow GC
Article: INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT. 2019;34(4):1439-1455
Exploring staff experience of economic efficiency requirements in health care: A mixed method study
Korlen S; Amer-Wahlin I; Lindgren P; Schwarz UVT
Journal article: JOURNAL OF CLINICAL LIPIDOLOGY. 2019;13(3):e31
An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Article: INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE. 2019;31(4):276-282
Inter-hospital variations in health outcomes in childbirth care in Sweden: a register-based study
Mesterton J; Brommels M; Ladfors L; Lindgren P; Amer-Wahlin I
Article: DISABILITY AND REHABILITATION. 2019;41(8):966-973
Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis
Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmuller H; Lindgren P
Journal article: ORPHANET JOURNAL OF RARE DISEASES. 2019;14(1):75
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
Landfeldt E; Lochmueller H; Lindgren P
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(1):15-24
Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method
Landfeldt E; Zethraeus N; Lindgren P
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2019;35(S1):69
PP170 Quantifying the Life-Cycle Value of Second Generation Antipsychotics
Berdud M; Wallin-Bernhardsson N; Zamora B; Lindgren P; Towse A
Article: BMC HEALTH SERVICES RESEARCH. 2018;18(1):963
The development and validation of a scale to explore staff experience of governance of economic efficiency and quality (GOV-EQ) of health care
Korlen S; Richter A; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV. 2018;30(9):1090-1098
Excess costs of non-infectious comorbidities among people living with HIV - estimates from Denmark and Sweden
Hjalte F; Calara PS; Blaxhult A; Helleberg M; Wallace K; Lindgren P
Article: MUSCLE & NERVE. 2018;58(3):367-373
Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis
Landfeldt E; Mayhew A; Straub V; Lochmueller H; Bushby K; Lindgren P
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy563.p4389
P4389Favourable long-term effects of a cardiovascular prevention program in primary health care in Sweden in men, and women on first cardiovascular events, cardiovascular mortality, and all-cause mortality
Journath G; Hammar N; Hammar N; Vikstrom M; Linnersjo A; Linnersjo A; Walldius G; Krakau I; Lindgren P; Lindgren P; De Faire U; Hellenius ML
Article: PLOS ONE. 2018;13(6):e0199170
Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study
Willers C; Iderberg H; Axelsen M; Dahlstrom T; Julin B; Leksell J; Lindberg A; Lindgren P; Muth KL; Svensson A-M; Lilja M
Article: LAKARTIDNINGEN. 2018;115:E399
[Leaders as intermediates between economic incentive models and professional motivation].
Korlén S; Essén A; Lindgren P; Amer-Wåhlin I; von Thiele Schwarz U
Article: DIABETES-METABOLISM RESEARCH AND REVIEWS. 2018;34(4):e2984
Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden
Julin B; Willers C; Leksell J; Lindgren P; Muth KL; Svensson A-M; Lilja M; Dahlstrom T
Journal article: NEUROMUSCULAR DISORDERS. 2018;28(1):100
Compliance to care guidelines for Duchenne muscular dystrophy in Italy
Landfeldt E; Lindgren P; Guglieri M; Lochmuller H; Bushby K
Article: JAMA CARDIOLOGY. 2017;2(10):1069-1078
Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
Article: HEALTH SERVICES MANAGEMENT RESEARCH. 2017;30(3):148-155
Professionals' perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement
Korlen S; Amer-Wahlin I; Lindgren P; Schwarz UVT
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2017;96(5):597-606
Case mix adjusted variation in cesarean section rate in Sweden
Mesterton J; Ladfors L; Abreu AE; Lindgren P; Saltvedt S; Weichselbraun M; Amer-Wahlin I
Journal article: GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT. 2017;4(1):100-103
Mortality Cost of Duchenne Muscular Dystrophy
Landfeldt E; Eagle M; Straub V; Lochmüller H; Bushby K; Lindgren P
Article: JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT. 2017;31(2):126-141
Managerial strategies to make incentives meaningful and motivating
Korlen S; Essen A; Lindgren P; Amer-Wahlin I; Schwarz UVT
Article: CLINICAL THERAPEUTICS. 2017;39(4):771-786.e3
Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; van Hout B
Journal article: JOURNAL OF CANCER POLICY. 2017;11:12-18
Assessment of value for resource allocation in cancer care
Lindgren P; Jonsson B; Wilking N
Article: PHARMACOECONOMICS. 2017;35(2):249-258
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
Landfeldt E; Alfredsson L; Straub V; Lochmuller H; Bushby K; Lindgren P
Journal article: GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT. 2017;4(1):grhta.5000260
Mortality cost of Duchenne muscular dystrophy
Landfeldt E; Eagle M; Straub V; Lochmuller H; Bushby K; Lindgren P
Journal article: EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY. 2016;206:e161
Case mix adjusted variation in cesarean section rate in Sweden
Ladfors L; Amer-Wåhlin I; Saltvedt S; Weichselbraun M; Abreu AE; Lindgren P; Mesterton J
Journal article: ANNALS OF ONCOLOGY. 2016;27:vi475
1368P Access to cancer drugs in Europe years 2005-2014
Wilking N; Lindgren P; Wilking U; Jönsson B
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170
The cost and burden of cancer in the European Union 1995-2014
Jonsson B; Hofmarcher T; Lindgren P; Wilking N
Article: JMIR RESEARCH PROTOCOLS. 2016;5(3):e188
A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study.
Leppänen A; Lindgren P; Sundberg CJ; Petzold M; Tomson T
Article: CLINICAL CARDIOLOGY. 2016;39(6):313-320
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Article: BMC PREGNANCY AND CHILDBIRTH. 2016;16(1):125
Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study
Mesterton J; Lindgren P; Abreu AE; Ladfors L; Lilja M; Saltvedt S; Amer-Wahlin I
Article: JOURNAL OF NEUROLOGY. 2016;263(5):906-915
Quantifying the burden of caregiving in Duchenne muscular dystrophy
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmuller H; Bushby K
Article: DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY. 2016;58(5):508-515
Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Journal article: NEUROMUSCULAR DISORDERS. 2016;26(4-5):329
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT) (vol 25, pg 937, 2015)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmiiller H; Bushby K
Article: NEUROMUSCULAR DISORDERS. 2015;25(12):937-944
Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT)
Landfeldt E; Mayhew A; Eagle M; Lindgren P; Bell CF; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: PLOS ONE. 2015;10(11):e0140201
Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden
Journath G; Hammar N; Elofsson S; Linnersjo A; Vikstrom M; Walldius G; Krakau I; Lindgren P; de Faire U; Hellenius M-L
Journal article: CIRCULATION. 2015;132(suppl_3)
Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom
Taylor B; Lothgren M; Villa G; Lindgren P; Van Hout B; Mark D
Article: VALUE IN HEALTH. 2015;18(4):439-448
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
Berg J; Lindgren P; Mejhert M; Edner M; Dahlstrom U; Kahan T
Article: JOURNAL OF NEUROMUSCULAR DISEASES. 2015;2(1):63-72
Compliance to Care Guidelines for Duchenne Muscular Dystrophy.
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmüller H; Bushby K
Journal article: GESUNDHEITSOKONOMIE UND QUALITATSMANAGEMENT. 2014;19(6):263-271
Cost-effectiveness of Dronedarone in Comparison with Relevant Treatment Alternatives in Germany
Nilsson J; Akerborg O; Seifert C; Rosenfeld S; Lindgren P
Article: NEUROLOGY. 2014;83(6):529-536
The burden of Duchenne muscular dystrophy An international, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmueller H; Bushby K
Article: THROMBOSIS RESEARCH. 2014;133(2):162-167
Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesna P; Mesterton J; Lindgren P
Article: JRSM CARDIOVASCULAR DISEASE. 2014;3:2048004014548735
Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2013;29(10):1249-1255
Cost-Effectiveness of Dronedarone in Patients With Atrial Fibrillation in the ATHENA Trial
Berg J; Sauriol L; Connolly S; Lindgren P
Journal article: EUROPEAN HEART JOURNAL. 2013;34(suppl_1):p1490
Long-term morbidity and mortality in patients hospitalised with systolic heart failure, and the impact of health-related quality of life
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2013;14(3):481-493
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation-results for Canada, Italy, Sweden and Switzerland
Nilsson J; Akerborg O; Bego-Le Bagousse G; Rosenquist M; Lindgren P
Article: EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2013;24(3):260-265
Long term health care consumption and cost expenditure in systolic heart failure
Mejhert M; Lindgren P; Schill O; Edner M; Persson H; Kahan T
Journal article: CLINICOECONOMICS AND OUTCOMES RESEARCH. 2013;5:19-28
Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model
Reynolds MR; Nilsson J; Akerborg O; Jhaveri M; Lindgren P
Journal article: VALUE IN HEALTH. 2012;15(7):a422
PCN75 Survival and Costs in Metastatic Renal Cell Carcinoma: A Comparison of mRCC Treatment Pre- and Post Tyrosine Kinase Inhibitor (TKI) Introduction Using Retrospective Registry Data
Jönsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandström P; Ljungberg B; Jakobsson M
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(4):445-450
Cost-effectiveness of statins revisited: lessons learned about the value of innovation
Lindgren P; Jonsson B
Article: CLINICAL THERAPEUTICS. 2012;34(8):1788-1802
Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland
Akerborg O; Nilsson J; Bascle S; Lindgren P; Reynolds M
Article: PHARMACOECONOMICS. 2012;30(6):513-530
Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode
Ekman M; Lindgren P; Miltenburger C; Meier G; Locklear JC; Chatterton ML
Article: THROMBOSIS RESEARCH. 2012;129(5):e233-e237
Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic
Salaj P; Penka M; Smejkal P; Geierova V; Ovesna P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Article: ACTA PSYCHIATRICA SCANDINAVICA. 2011;124(3):214-225
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder
Kasteng F; Eriksson J; Sennfalt K; Lindgren P
Article: EUROPACE. 2011;13(1):23-30
Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries
Holstenson E; Ringborg A; Lindgren P; Coste F; Diamand F; Nieuwlaat R; Crijns H
Journal article: VALUE IN HEALTH. 2010;13(7):a355
PCV75 CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION
Nilsson J; Åkerborg Ö; Lindgren P; Bascle S
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2010;64(9):1228-1234
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial
Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETES & METABOLISM. 2010;36(3):198-203
Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes
Ringborg A; Lindgren P; Yin DD; Martinell M; Stalhammar J
Article: HAEMOPHILIA. 2010;16(3):487-494
The value of early treatment in patients with haemophilia and inhibitors
Kavakli K; Yesilipek A; Antmen B; Aksu S; Balkan C; Yilmaz D; Kupesiz A; Sasmaz I; Lindgren P; Mesterton J
Article: QUALITY OF LIFE RESEARCH. 2010;19(3):381-390
Factors determining utility measured with the EQ-5D in patients with atrial fibrillation
Berg J; Lindgren P; Nieuwlaat R; Bouin O; Crijns H
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;38(6):409-418
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G; Lindgren P; Geborek P
Article: CANADIAN JOURNAL OF CARDIOLOGY. 2009;25(11):e362-e369
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Joensson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(5):576-582
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden
Ringborg A; Yin DD; Martinell M; Stalhammar J; Lindgren P
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2009;63(7):997-1007
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS)
Ringborg A; Cropet C; Jonsson B; Gagliardino JJ; Ramachandran A; Lindgren P
Article: ATHEROSCLEROSIS SUPPLEMENTS. 2009;10(1):3-21
Bridging science and health policy in cardiovascular disease: focus on lipid management A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention - Health Policy, in Venice, Italy, on 25 October, 2008
Atella V; Brady A; Catapano AL; Critchley J; Graham IM; Hobbs FDR; Leal J; Lindgren P; Vanuzzo D; Volpe M; Wood D; Paoletti R
Article: MULTIPLE SCLEROSIS JOURNAL. 2009;15(6):741-751
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions
Kobelt G; Texier-Richard B; Lindgren P
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2009;25(2):181-189
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
Lindgren P; Geborek P; Kobelt G
Article: ALLERGY. 2009;64(3):431-438
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom
Price D; Berg J; Lindgren P
Journal article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2009;:1-10
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
Kobelt G; Lindgren P; Geborek P
Article: PHARMACOECONOMICS. 2009;27(3):221-230
The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone Results from ASCOT
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: DIABETIC MEDICINE. 2008;25(10):1178-1186
Prevalence and incidence of Type 2 diabetes and its complications 1996-2003 -: estimates from a Swedish population-based study
Ringborg A; Lindgren P; Martinell M; Yin DD; Schon S; Stalhammar J
Article: MULTIPLE SCLEROSIS JOURNAL. 2008;14(5):679-690
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2008;62(5):708-716
Resource use and costs of type 2 diabetes in Sweden -: estimates from population-based register data
Ringborg A; Martinell M; Stalhammar J; Yin DD; Lindgren P
Article: JOURNAL OF CARDIOVASCULAR RISK. 2008;15(2):230-233
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader E-L; Jonsson B
Article: EUROPACE. 2008;10(4):403-411
Costs of atrial fibrillation in five European countries:: results from the Euro Heart Survey on atrial fibrillation
Ringborg A; Nieuwlaat R; Lindgren P; Joensson B; Fidan D; Maggioni AP; Lopez-Sendon J; Stepinska J; Cokkinos DV; Crijns HJGM
Article: RESPIRATORY MEDICINE. 2008;102(2):219-231
Economic evaluation of FE_NO measurement in diagnosis and 1-year management of asthma in Germany
Berg J; Lindgren P
Journal article: HEART. 2008;94(2):e4
Economic evaluation of ASCOT-BPLA:: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Article: CLINICAL THERAPEUTICS. 2007;29(6):1184-1202
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: A European model based on the CLARITY and COMMIT trials
Berg J; Lindgren P; Spiesser J; Parry D; Jonsson B
Article: EUROPEAN HEART JOURNAL. 2007;28(12):1448-1453
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jonsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):51-57
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
Brueggenjuergen B; Lindgren P; Ehlken B; Rupprecht H-J; Willich SN
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(1):25-30
Utility loss and indirect costs following cardiovascular events in hypertensive patients:: the ASCOT health economic substudy
Lindgren P; Kahan T; Poulter N; Buxton M; Svarvar P; Dahlof B; Jonsson B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2007;23(2):177-183
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective
Lindgren P; Lindstrom J; Tuomilehto J; Uusitupa M; Peltonen M; Jonsson B; de Faire U; Hellenius M-L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:5-13
Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
Kobelt G; Berg J; Lindgren P; Jönsson B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:55-64
Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:75-85
Costs and quality of life of multiple sclerosis in Sweden.
Berg J; Lindgren P; Fredrikson S; Kobelt G
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:96-104
Costs and quality of life of multiple sclerosis in the United Kingdom.
Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:65-74
Costs and quality of life of multiple sclerosis in Spain.
Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA; Associación Española de Esclerosis Múltiple
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:14-23
Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:86-95
Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:34-44
Costs and quality of life of multiple sclerosis in Germany.
Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2006;7 Suppl 2:45-54
Costs and quality of life of multiple sclerosis in Italy.
Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2006;77(8):918-926
Costs and quality of life of patients with multiple sclerosis in Europe
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jonsson B
Journal article: PHARMACOECONOMICS - SPANISH RESEARCH ARTICLES. 2006;3(3):123-135
Coste-efectividad de atorvastatina en hipertensos con riesgo moderado: evaluación económica del estudio ASCOT-LLA
Gómez CC; de Bobadilla JF; Vargas MG; Lindgren P; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DDP; Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(4):354-362
The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Ringborg A; Lindgren P; Jönsson B
Article: RHEUMATOLOGY. 2005;44(9):1169-1175
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Article: ANNALS OF THE RHEUMATIC DISEASES. 2005;64(8):1174-1179
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
Kobelt G; Lindgren P; Singh A; Klareskog L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:68-73
Cost of Parkinson's disease in Europe
Lindgren P; von Campenhausen S; Spottke E; Siebert U; Dodel R
Journal article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2005;12(1):29-36
Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(1):29-36
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B
Article: CLINICAL THERAPEUTICS. 2005;27(1):100-110
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Article: JOURNAL OF CARDIOVASCULAR RISK. 2004;11(6):460-465
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study
Lamy A; Jönsson B; Weintraub WS; Zhao F; Chrolavicius S; Bakhai A; Culler S; Gafni A; Lindgren P; Mahoney E; Yusuf S
Article: JOURNAL OF INTERNAL MEDICINE. 2004;255(5):562-570
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden:: a long-term model based on the cure trial
Lindgren P; Jönsson B; Yusuf S
Journal article: PHARMACOECONOMICS - GERMAN RESEARCH ARTICLES. 2004;2(1):31-41
Die Langzeit-Kosteneffektivität von Clopidogrel zusätzlich zu Azetylsalizylsäure bei Patienten mit akutem Koronarsyndrom ohne ST-Streckenhebung im österreichischen Gesundheitssystem
Schwarz B; Lindgren P; Nanz S
Article: PREVENTIVE MEDICINE. 2003;36(4):403-409
Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm -: a stochastic model of exercise and dietary advice
Lindgren P; Fahlstadius P; Hellenius ML; Jönsson B; de Faire U
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):37-42
The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden.
Lindgren P; Jönsson B; Duchane J
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319
Modeling the progression of rheumatoid arthritis - A two-country model to estimate costs and consequences of rheumatoid arthritis
Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2002;3(3):180-187
Modelling the costs and effects of leflunomide in rheumatoid arthritis.
Kobelt G; Lindgren P; Young A
Article: PHARMACOECONOMICS. 2002;20(2):101-108
Cost-effectiveness analysis of exemestane compared with Megestrol in advanced breast cancer -: A model for Europe and Australia
Lindgren P; Jönsson B; Redaelli A; Radice D
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2001;2(2):60-68
Costs and quality of life in multiple sclerosis
Kobelt G; Lindgren P; Smala A; Bitsch A; Haupts M; Kölmel HW; König N; Rieckmann P; Zettl UK; the German Cost of MS Study Group
Article: PHARMACOECONOMICS. 1999;16(4):409-416
Costs of mini mental state examination-related cognitive impairment
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease:: A Markov model
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Show more

All other publications

Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025;91:56-66
Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia
Solmi M; Croatto G; Fabiano N; Wong S; Gupta A; Fornaro M; Schneider LK; Rohani-Montez SC; Fairley L; Smith N; Bitter I; Gorwood P; Taipale H; Tiihonen J; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Vieta E; De Prisco M; Boyer L; Hojlund M; Correll CU
Review: EUROPEAN UROLOGY. 2024;86(5):400-408
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
Vynckier P; Annemans L; Raes S; Amrouch C; Lindgren P; Májek O; Beyer K; Leenen RCA; Venderbos LDF; Denijs F; van Harten MJ; Helleman J; Chloupková R; Briers E; Vasilyeva V; Rivas JG; Basu P; Chandran A; van den Bergh RCN; Collen S; Van Poppel H; Roobol MJ; Members of the PRAISE-U Consortium
Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;88:6-20
Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
Solmi M; Croattog G; Gupta A; Fabianoa N; Wong S; Fornaro M; Schneiderl LK; Rohani-Montez SC; Fairleyl L; Smithl N; Bitterm I; Gorwoodn P; Taipalep H; Tiihonenp J; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfortay D; De Prisco M; Boyer L; Vieta E; Correlle CU
Review: EXPERT OPINION ON DRUG SAFETY. 2024;23(10):1249-1269
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Solmi M; Miola A; Capone F; Pallottino S; Hojlund M; Firth J; Siskind D; Holt RIG; Corbeil O; Cortese S; Dragioti E; Du Rietz E; Nielsen RE; Nordentoft M; Fusar-Poli P; Hartman CA; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Vieta E; Taipale H; Correll CU
Review: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2024;80:55-69
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
Solmi M; Croatto G; Fornaro M; Schneider LK; Rohani-Montez SC; Fairley L; Smith N; Bitter I; Gorwood P; Taipale H; Tiihonen J; Cortese S; Dragiotiu E; Du Rietz E; Nielsen RE; Firth J; Fusar-Poli P; Hartman C; Holt RIG; Hoye A; Koyanagi A; Larsson H; Lehto K; Lindgren P; Manchia M; Nordentoft M; Skonieczna-Zydecka K; Stubbs B; Vancampfort D; Boyer L; De Prisco M; Vieta E; Correll CU
Conference publication: VALUE IN HEALTH. 2023;26(12):S196-S197
COST-EFFECTIVENESS OF RENAL DENERVATION FOR UNCONTROLLED HYPERTENSION: AN ANALYSIS FOR SWEDEN BASED ON THE SPYRAL HTN-ON MED TRIAL AND OTHER CONTEMPORARY EVIDENCE
Kahan T; Johansen ML; Ryschon AM; Cao K; Kolovetsios M; Lindgren P; Pietzsch J
Conference publication: VALUE IN HEALTH. 2022;25(12):S156
A GLOBAL ANALYSIS OF THE VALUE OF PRECISION MEDICINE IN ONCOLOGY - THE CASE OF NON-SMALL CELL LUNG CANCER
Hofmarcher T; Malmberg C; Lindgren P
Conference publication: ANNALS OF ONCOLOGY. 2021;32:S1025
Diagnosed with non-small cell lung cancer but not treated
Hofmarcher T; Wilking N; Lindgren P
Conference publication: VALUE IN HEALTH. 2020;23:S493
THE IMPACT ON CLINICAL AN ECONOMIC VALUE OF PATIENT PRIORITIZATION ACCORDING TO RISK: EVOLOCUMAB IN PATIENTS WITH MYOCARDIAL INFARCTION IN SWEDEN
Hagstrom E; Lindgren P; Villa G; Martinez L; Arellano J; Svensson EM; Fonarow GC
Conference publication: ATHEROSCLEROSIS. 2020;315:E36
COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN BELGIUM
Descamps OS; Van Hout B; Lindgren P; Villa G; Urbich M; Fonarow GC
Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1197
A comparative study on costs of cancer and access to medicines in Europe
Wilking N; Bradvik G; Lindgren P; Svedman C; Jonsson B; Hofmarcher T
Conference publication: DIABETOLOGIA. 2020;63(SUPPL 1):S121
Costs of diabetes complications: hospital based care and production loss for 392,200 people with type 2 diabetes and matched controls in Sweden
Carlsson KS; Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Jendle J
Conference publication: DIABETES. 2020;69
Costs of Diabetes Complications: Hospital-Based Care and Production Loss for 392,200 People with Type 2 Diabetes and Matched Controls
Andersson E; Persson S; Hallen N; Ericsson A; Thielke D; Lindgren P; Carlsson KS; Jendle JH
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15):s1197
A comparative study on costs of cancer and access to medicines in Europe.
Wilking NE; Bradvik G; Lindgren P; Svedman C; Jonsson B; Hofmarcher T
Conference publication: VALUE IN HEALTH. 2020;23:S172
SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C
Lofvendahl S; Bradvik G; Weiland O; Lindgren P
Review: HEALTH POLICY. 2020;124(4):404-410
Risk sharing in managed entry agreements-A review of the Swedish experience
Andersson E; Svensson J; Persson U; Lindgren P
Conference publication: VALUE IN HEALTH. 2019;22:S548
COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN
Lindgren P; Hagstrom E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Sibartie M; Fonarow GC
Conference publication: VALUE IN HEALTH. 2019;22:S685
ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE
Berdud M; Bernhardsson WN; Talaya ZMB; Lindgren P; Towse A
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:681
Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
Lindgren P; Hagstrom E; Van Hout B; Villa G; Urbich M; Sandelin R; Svensson ME; Fonarow GC
Published conference paper: JAMA CARDIOLOGY. 2019;4(7):691-695
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:879
Favourable long-term effects of a cardiovascular prevention program in primary health care in Sweden in men, and women on first cardiovascular events, cardiovascular mortality, and all-cause mortality
Journath G; Hammar N; Hammar N; Vikstrom M; Linnersjo A; Linnersjo A; Walldius G; Krakau I; Lindgren P; De Faire U; Hellenius ML
Conference publication: INTERNATIONAL JOURNAL OF INTEGRATED CARE. 2018;18:61
Social and economic impact of a case management approach for people with rare and complex conditions in Salaj, Romania
Sparring V; Tschank J; Handler K; Mansoory E; Konzett-Smoliner S; Lindgren P
Review: JOURNAL OF NEUROMUSCULAR DISEASES. 2017;4(4):285-292
Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review.
Landfeldt E; Edström J; Lindgren P; Lochmüller H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:6535
Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status.
Wilking NE; Jonsson B; Lindgren P; Wilking U
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2017;69(11):1852
OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM
Danese M; Villa G; Taylor B; Lindgren P; Van Hout B; Lothgren M
Review: PHARMACOECONOMICS. 2017;35(3):297-318
A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies
Wei C-Y; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
Conference publication: VALUE IN HEALTH. 2016;19(7):A651-A652
COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; van Hout B
Conference publication: VALUE IN HEALTH. 2016;19(7):A524
ESTIMATING THE ECONOMIC BURDEN ASSOCIATED WITH THE EARLY STAGES OF PROGRESSION OF ALZHEIMER'S DISEASE IN EUROPE
Lindgren P; Jonsson L; Coste F; Chan E; Bosshard R
Conference publication: ANNALS OF ONCOLOGY. 2016;27
Access to cancer drugs in Europe years 2005-2014
Wilking N; Lindgren P; Wilking U; Jonsson B
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):e18015
Access to cancer drugs in Europe years 2005-2014
Wilking NE; Lindgren P; Wilking U; Jonsson B
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):6620
Is there a link between value as defined by ESMO-MCBS and uptake of new drugs?
Lindgren P; Jonsson B; Hofmarcher T; Wilking NE
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):6618
The burden and direct cost of cancer in Europe (EU-28)
Wilking NE; Hofmarcher T; Lindgren P; Jonsson B
Conference publication: VALUE IN HEALTH. 2016;19(3):A3
COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
Gandra SR; Villa G; Fonarow G; Lothgren M; Lindgren P; Somaratne R; van Hout B
Conference publication: VALUE IN HEALTH. 2015;18(7):A569
ASSESSING THE ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE FROM A HEALTH ECONOMICS PERSPECTIVE
Lindgren P; Jonsson B; Wilking N
Conference publication: DIABETOLOGIA. 2015;58:S140-S141
Determinants of HbA_1c in patients with type 1 diabetes in seven Swedish county councils
Lilja M; Julin B; Andersson G; Andersson I-L; Axelsen M; Ek M; Kristiansson R; Lekell J; Lindberg A; Lindgren P; Londahl F; Muth KL; Svensson A-M; Dahlstrom T
Conference publication: EUROPEAN HEART JOURNAL. 2015;36:1201
Long-term effects of a cardiovascular prevention program in primary health care in Sweden
Journath G; Hammar N; Linnersjo A; Vikstrom M; Walldius G; Krakau I; Lindgren P; De Faire U; Hellenius M-L
Conference publication: VALUE IN HEALTH. 2015;18(3):A145
DETERMINANTS OF UTILITY BASED ON THE EQ-5D IN CHRONIC HEART FAILURE PATIENTS AND THEIR CHANGE OVER TIME: RESULTS FROM THE SWEDISH HEART FAILURE REGISTRY
Berg J; Lindgren P; Mejhert M; Edner M; Dahlstrom U; Kahan T
Conference publication: VALUE IN HEALTH. 2014;17(7):A558
DETERMINISTIC VERSUS STOCHASTIC PREDICTION OF RISK FOR CARDIOVASCULAR EVENTS
Villa G; Lothgren M; Gandra SR; Lindgren P; van Hout B
Conference publication: NEUROMUSCULAR DISORDERS. 2014;24(9-10):853
The burden of Duchenne muscular dystrophy: An international, cross-sectional study
Landfeldt E; Lindgren P; Bell CF; Schmitt C; Guglieri M; Straub V; Lochmuller H; Bushby K
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2014;16:347
Health-related quality of life in chronic heart failure patients in Sweden: results from the Swedish Heart Failure Registry
Berg J; Mejhert M; Lindgren P; Edner M; Dahlstrom U; Kahan T
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:287
Long-term morbidity and mortality in patients hospitalised with systolic heart failure, and the impact of health-related quality of life
Berg J; Lindgren P; Kahan T; Schill O; Persson H; Edner M; Mejhert M
Conference publication: VALUE IN HEALTH. 2012;15(7):A551
LONG-TERM EFFECTS ON COSTS AND QUALITY ADJUSTED LIFE YEARS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS TREATED WITH LAQUINIMOD: RESULTS BASED ON THE ALLEGRO AND BRAVO TRIALS
Lang A; Tuomari A; Kobelt G; Lindgren P
Conference publication: VALUE IN HEALTH. 2012;15(7):A422
SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE- AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA
Jonsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandstrom P; Ljungberg B; Jakobsson M
Conference publication: VALUE IN HEALTH. 2012;15(4):A122
COST-EFFECTIVENESS OF DRONEDARONE IN NON-PERMANENT ATRIAL FIBRILLATION IN TURKEY COMPARED TO STANDARD TREATMENT, AMIODARONE AND SOTALOL
Sahin T; Nilsson J; Akerborg O; Lindgren P; Yesil A; Topcu T
Meeting abstract: VALUE IN HEALTH. 2011;14(7):A317
COST OFFSETS AND GAINS IN HEALTH EFFECTS IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH LAQUINIMOD: AN ANALYSIS BASED ON THE ALLEGRO TRIAL
Ekman M; White RE; Buck PE; Justo N; Lindgren P
Conference publication: VALUE IN HEALTH. 2011;14(3):A112-A113
A NET BENEFIT FRAMEWORK (NBF) ANALYSIS OF CHART DATA FOR HAEMOPHILIA INHIBITOR PATIENTS
Weatherall J; Mesterton J; Lindgren P; Dalen J
Conference publication: VALUE IN HEALTH. 2011;14(3):A14-A15
ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING SPECTRAL GRAPH THEORY
Lindgren P; Akerborg O
Conference publication: EUROPEAN HEART JOURNAL. 2010;31:227
Canadian cost-effectiveness analysis of dronedarone in patients with atrial fibrillation based on the ATHENA trial
Berg J; Sauriol L; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2010;13(3):A58
RESOURCE CONSUMPTION AND COSTS OF CARE THE YEAR BEFORE AND AFTER INITIATION OF INSULIN THERAPY IN SWEDISH PATIENTS WITH TYPE 2 DIABETES
Pettersson B; Lindgren P; Ringborg A; Martinell M; Stalhammar J
Conference publication: CIRCULATION. 2009;120(18):S484-S485
The Economic Consequences of Non-Adherence to Lipid-Lowering Therapy: Results From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren P; Eriksson J; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2009;12(7):A335
DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES
Akerborg O; Bascle S; Lindgren P
Review: VALUE IN HEALTH. 2009;12(6):857-871
Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model
Schwander B; Gradl B; Zoellner Y; Lindgren P; Diener H-C; Lueders S; Schrader J; Antonanzas Villar F; Greiner W; Jonsson B
Review: JOURNAL OF CARDIOVASCULAR RISK. 2009;16(2):138-143
From 4S to IDEAL: the health economics of the statin trials
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A548
COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
Kobelt G; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A410
FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION
Berg J; Lindgren P; Nieuwlaat R; Bascle S; Crijns H
Conference publication: DIABETOLOGIA. 2008;51:S425
Resource use associated with type 2 diabetes in 24 countries in Asia, Latin America, the Middle East and Africa
Mechiche S; Ringborg A; Lindgren P; Bengt J; Ramachandran A; Gagliardino JJ
Published conference paper: CURRENT MEDICAL RESEARCH AND OPINION. 2008;24(7):2089-2101
Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials
Berg J; Fidan D; Lindgren P
Conference publication: THORAX. 2007;62:A131
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the UK
Berg J; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(6):A414
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation - A European model based on the clarity and commit trials: Adaptation to Hungary
Berg J; Odhiambo R; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(6):A239-A240
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared to current standard practice in Sweden
Kobelt G; Berg J; Lindgren P; Hillert J
Conference publication: VALUE IN HEALTH. 2007;10(6):A385-A386
Economic evaluation of interferon-Å-1b in the treatment of patients with a clinically isolated syndrome (CIS)
Kobelt G; Lindgren P; Miltenburger C; Hillert J
Conference publication: VALUE IN HEALTH. 2007;10(6):A419
Economic evaluation of 80 mg atorvastatin compared to 20-40 mg simvastatin in patients with acute coronary syndromes
Lindgren P; Olsson AG; Pedersen T; Joensson B
Conference publication: VALUE IN HEALTH. 2007;10(6):A410
Health insurance costs of stroke hospital treatments in Hungary; 2003-2005
Karpati K; Boncz I; Lindgren P; Ekman M; Brodszky V; Majer I; Bereczki D; Gulacsi L
Conference publication: VALUE IN HEALTH. 2007;10(6):A237-A238
The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, United Kingdom, and Sweden
Schwander B; Lindgren P; Gradl B
Corrigendum: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2007;8(4):359
Costs and quality of life in multiple sclerosis in The Netherlands (vol 7, pg S55, 2006)
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJH; Polman C; Uitdehaag B
Conference publication: CIRCULATION. 2007;116(16):793
Cost-effectiveness of clopidogrel in percutaneous coronary intervention based on a meta-analysis of PCI-CURE, CREDO and PCI-CLARITY
Berg J; Fidan D; Jackson J; Lindgren P
Conference publication: EUROPEAN HEART JOURNAL. 2007;28:857
Amlodipine plus atorvastatin is cost-effective compared to atenolol plus atorvastatin, amlodipine or atenolol alone: The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Lindgren P; Buxton M; Kahan T; Poulter N; Dahlof B; Sever PS; Wedel H; Jonsson B
Review: EUROPEAN HEART JOURNAL SUPPLEMENTS. 2007;9(C):C3-C74
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Qiao Q; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Luis Zamorano J; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; GohIke H; Gonzalez Juanatey JR; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Conference publication: JOURNAL OF HYPERTENSION. 2007;25:S137
An amlodipine-based regimen is cost-effective compared to an atenolol-based regimen:: Results from the Anglo-Scandinavian cardiac outcomes trial
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlof B; Sever PS; Wedel H; Jonsson B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2007;8(1):197-198
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the IDEAL trial
Lindgren P; Jonsson B
Conference publication: DIABETES. 2007;56:A156-A157
Time to insulin treatment and factors influencing prescription in Swedish type 2 diabetics
Ringborg A; Lindgren P; Yin DD; Martinell M; Stalhammar J
Conference publication: CIRCULATION. 2007;115(21):E568
Cost-effectiveness of multi-drug regimen of amlodipine plus atorvastatin based on the anglo-scandinavian cardiac outcomes trial (ASCOT):: An economic sub-analysis
Koren M; Lindgren P; Buxton M; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; Tang SS; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A110
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in the US
Berg J; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A64
Determination of health care costs incurred by swedish patients with type 2 diabetes
Ringborg A; Stalhammar J; Martinell D; Lindgren P
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007;49(9):392A
Economic evaluation of the anglo-Scandinavian cardiac outcomes trial (ASCOT)-blood pressure lowering arm (BPLA):: A sub-study on incremental cost-effectiveness of amlodipine-based regimen vs. atenolol-based regimen in primary prevention among hypertensive patients with additional risk factors
Lindgren P; Tang S; Buxton M; Kahan T; Poulter N; Dahlof B; Sever P; Wedel H; Buch J; Jonsson B
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2007;49(9):294A-295A
Economic evaluation of intensive atorvastatin compared to standard simvastatin in patients with acute coronary syndrome from the IDEAL trial
Lindgren P; Jonsson B
Review: EUROPEAN HEART JOURNAL. 2007;28(1):88-136
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Ryden L; Standl E; Bartnik M; Van den Berghe G; Betteridge J; de Boer M-J; Cosentino F; Jonsson B; Laakso M; Malmberg K; Priori S; Ostergren J; Tuomilehto J; Thrainsdottir I; Vanhorebeek I; Stramba-Badiale M; Lindgren P; Priori SG; Blanc J-J; Budaj A; Camm J; Dean V; Deckers J; Dickstein K; Lekakis J; McGregor K; Metra M; Morais J; Osterspey A; Tamargo J; Zamorano JL; Deckers JW; Bertrand M; Charbonnel B; Erdmann E; Ferrannini E; Flyvbjerg A; Gohlke H; Juanatey JRG; Graham I; Monteiro PF; Parhofer K; Pyorala K; Raz I; Schernthaner G; Volpe M; Wood D
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A353
Cost-utility analysis of eprosartan compared to enalapril and ramipril in the treatment of moderate to severe hypertension in Sweden
Lindgren P; Schwander B; Zollner Y; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A346-A347
Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation:: European model results based on clarity and commit
Berg J; Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A333
Economic evaluation of a new airway inflammation monitor in the diagnosis and management of asthma in Germany
Berg J; Lindgren P; Joensson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A330
Utility loss and indirect costs after stroke in Sweden
Lindgren P; Glader EL; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231-A232
Cost of inpatient and outpatient care of Swedish patients with diabetes mellitus
Ringborg A; Berwick S; Stalhammar J; Martinell M; Lindgren P
Meeting abstract: VALUE IN HEALTH. 2006;9(6):A231
Cost of a major hypoglycaemic event in type 1 and type 2 diabetic patients - A systematic literature review
Lilja U; Asmussen M; Lindgren P
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2006;12:S120-S121
The costs and quality of life of multiple sclerosis in Europe
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jonsson B
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:673
Determinants of cholesterol goal attainment at 12 months in patients not at goal after 3 months treatment with lipid lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:579
The cost of atrial fibrillation management in Europe: a cross-sectional study on resource use during admissions and outpatient clinic visits in the Euro Heart Survey cohort
Nieuwlaat R; Ringborg A; Lindgren P; Le Heuzey JY; Jonsson B; Gabriel S; Crijns HJ
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:378
Lifetime cost-effectiveness of atorvastatin 80 mg compared to generic simvastatin 20-40 mg in secondary prevention based on the IDEAL trial
Lindgren P; Jonsson B
Conference publication: EUROPEAN HEART JOURNAL. 2006;27:773
PCI reduces utility loss after myocardial infarctions in Sweden
Lindgren P; Stenestrand U; Hambraeus K; Wallentin L; Jonsson B
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2006;7(3):178
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial
Lindgren P; Jonsson B
Conference publication: CIRCULATION. 2006;113(21):E819
Trial based economic evaluation of intensive atorvastatin compared to standard simvastatin in the ideal trial
Lindgren P; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(6):A134
The cost of multiple sclerosis (MS) in Europe
Berg J; Kobelt G; Lindgren P; Fredrikson S; Jönsson B
Conference publication: CIRCULATION. 2005;112(17):U883
Atorvastatin therapy is cost-effective in individuals with treated hypertension, normal/mildly elevated cholesterol and ≥2 additional risk factors (ASCOT-LLA)
Schwartz JS; Lindgren P; Jonsson B; Mackell JA
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2005;11:S34
Cost of multiple sclerosis in Sweden:: changes in the last decade
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jönsson B
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:8
European Brain Council:: Epidemiology of brain diseases in Europe
Dodel R; Andlin-Sobocki P; Beghi E; Berg J; Jonsson L; Ekman M; Forsgren L; Jonsson B; Kobelt G; Lindgren P; Olesen J; Westphal M; Wittchen HU
Conference publication: EUROPEAN HEART JOURNAL. 2005;26:367
The cost-effectiveness of clopidogrel based on three trials
Lindgren P; Ringborg A; Jonsson B
Meeting abstract: VALUE IN HEALTH. 2005;8(3):253
9301 cost-effectiveness of long-term therapy with clopidogrel following percutaneous coronary intervention:: A Swedish analysis of the CREDO-trial
Ringborg A; Lindgren P; Jönsson B
Doctoral thesis: 2005
Modeling the economics of prevention
Lindgren P
Meeting abstract: VALUE IN HEALTH. 2004;7(6):694
Cost-effectiveness of reduction in cardiovascular outcomes with atorvastatin in patients with normal to mildly elevated cholesterol levels, treated for hypertension:: The ASCOT-LLA study
Lindgren P; Buxton MJ; Kahan T; Poulter N; Dahlöf B; Sever P; Wedel H; Jönsson B
Meeting abstract: VALUE IN HEALTH. 2004;7(6):688
The cost-effectiveness of clopidogrel in patients undergoing percutaneous coronary intervention in Sweden:: An analysis of PCI-cure
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Review: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S63-S66
Economic evidence in Parkinson's disease: a review.
Lindgren P
Meeting abstract: VALUE IN HEALTH. 2003;6(6):621
Short and long term cost-effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST segment elevation (ACS) in Scandinavian countries
Lindgren P; Jönsson B; Spiesser J; Carita P; Gabriel S
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2003;41(6):540A
Modeling the cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden
Lindgren P; Jonsson B
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2003;41(6):383A
Incremental cost-effectiveness of early and long-term clopidogrel in patients undergoing percutaneous coronary infarction in the CURE trial: The PCI-CURE economic analysis
Mehta SR; Weintraub WS; Jonsson B; Lamy A; Mahoney E; Lindgren P; Rather M; Bertrand ME; Zhao F; Chrolavicius S; Fox KA; Yusuf S
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:586
Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Carita P
Meeting abstract: EUROPEAN HEART JOURNAL. 2003;24:245
Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions: a five European countries analysis
Annemans L; Lindgren P; Frei A; Gabriel S; Spiesser J
Conference publication: CIRCULATION. 2002;106(19):758
The cost-effectiveness of the use of Clopidogrel in acute coronary syndromes based upon the CURE study
Lamy A; Chrolavicius S; Gafni A; Yusuf S; Zhao F; Jönsson B; Lindgren P; Bakhai A; Flather M; Fox KAA; Culler S; Mahoney EM; Weintraub WS
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S312
Economic consequences of the progression of rheumatoid arthritis in Sweden and the United Kingdom.
Kobelt G; Jonsson L; Lindgren P; Eberhardt K; Young A
Show more

Grants

Who reaps the value of medical innovation? The case of hepatitis C in Sweden
Bank of Sweden Tercentenary Foundation
31 October 2016 - 30 December 2018

Employments

Adjunct Professor, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, 2021-2029

Degrees and Education

Docent, Karolinska Institutet, 2014
Doctor Of Philosophy, Institute of Environmental Medicine, Karolinska Institutet, 2005

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI